Cargando…

Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG

OBJECTIVES: Myasthenia gravis (MG) is a rare, chronic, autoimmune neuromuscular disease which can affect functional and mental aspects of health and health-related quality of life (HRQoL). This study aims to obtain detailed knowledge of the impact of MG on HRQoL in a broad population from the perspe...

Descripción completa

Detalles Bibliográficos
Autores principales: Dewilde, Sarah, Philips, Glenn, Paci, Sandra, Beauchamp, Jon, Chiroli, Silvia, Quinn, Casey, Day, Laura, Larkin, Mark, Palace, Jacqueline, Berrih-Aknin, Sonia, Claeys, Kristl G, Muppidi, Srikanth, Mantegazza, Renato, Saccà, Francesco, Meisel, Andreas, Bassez, Guillaume, Murai, Hiroyuki, Janssen, MF
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890761/
https://www.ncbi.nlm.nih.gov/pubmed/36720569
http://dx.doi.org/10.1136/bmjopen-2022-066445
_version_ 1784881004432850944
author Dewilde, Sarah
Philips, Glenn
Paci, Sandra
Beauchamp, Jon
Chiroli, Silvia
Quinn, Casey
Day, Laura
Larkin, Mark
Palace, Jacqueline
Berrih-Aknin, Sonia
Claeys, Kristl G
Muppidi, Srikanth
Mantegazza, Renato
Saccà, Francesco
Meisel, Andreas
Bassez, Guillaume
Murai, Hiroyuki
Janssen, MF
author_facet Dewilde, Sarah
Philips, Glenn
Paci, Sandra
Beauchamp, Jon
Chiroli, Silvia
Quinn, Casey
Day, Laura
Larkin, Mark
Palace, Jacqueline
Berrih-Aknin, Sonia
Claeys, Kristl G
Muppidi, Srikanth
Mantegazza, Renato
Saccà, Francesco
Meisel, Andreas
Bassez, Guillaume
Murai, Hiroyuki
Janssen, MF
author_sort Dewilde, Sarah
collection PubMed
description OBJECTIVES: Myasthenia gravis (MG) is a rare, chronic, autoimmune neuromuscular disease which can affect functional and mental aspects of health and health-related quality of life (HRQoL). This study aims to obtain detailed knowledge of the impact of MG on HRQoL in a broad population from the perspective of the patient. DESIGN: Prospective, observational, digital, longitudinal real-world study. SETTING: Adult patients with MG from seven countries (USA, Japan, Germany, UK, Italy, Spain and Canada) downloaded a mobile application onto their phones and entered data about themselves and their MG. OUTCOME MEASURES: Data was collected using the following general and disease-specific patient-reported outcome measurements: EuroQol 5 Domains Health-Related Quality of Life Questionnaire (EQ-5D-5L), Myasthenia Gravis Activities of Daily Living (MG-ADL), Myasthenia Gravis Quality of Life 15-item revised scale (MG-QoL-15r), Hospital Anxiety and Depression Scale (HADS) and Health Utilities Index III (HUI3). Patients were categorised by their self-assessed Myasthenia Gravis Foundation of America (MGFA) class (I–V). RESULTS: Baseline results of 841 participants (mean age 47 years, 70% women) are reported. The distribution across the MGFA classes was: 13.9%, 31.0%, 38.1%, 15.5% and 1.6% for classes I–V. The MGFA class was a strong predictor of all aspects of HRQoL, measured with disease-specific and with generic instruments. The domains in which patients with MG most frequently mentioned problems were usual activities, anxiety and depression, tiredness, breathing and vision. The mean total MG-ADL Score was positively associated with increasing MGFA classes: 2.7, 4.4, 6.3 and 8.4 for MGFA classes I–IV. Mean baseline EQ-5D-5L utility was also associated with MGFA classes and was 0.817, 0.766, 0.648 and 0.530 for MGFA class I–IV. CONCLUSIONS: MG has a large impact on key aspects of health and HRQoL. The impact of this disease increases substantially with increasing disease severity.
format Online
Article
Text
id pubmed-9890761
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-98907612023-02-02 Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG Dewilde, Sarah Philips, Glenn Paci, Sandra Beauchamp, Jon Chiroli, Silvia Quinn, Casey Day, Laura Larkin, Mark Palace, Jacqueline Berrih-Aknin, Sonia Claeys, Kristl G Muppidi, Srikanth Mantegazza, Renato Saccà, Francesco Meisel, Andreas Bassez, Guillaume Murai, Hiroyuki Janssen, MF BMJ Open Neurology OBJECTIVES: Myasthenia gravis (MG) is a rare, chronic, autoimmune neuromuscular disease which can affect functional and mental aspects of health and health-related quality of life (HRQoL). This study aims to obtain detailed knowledge of the impact of MG on HRQoL in a broad population from the perspective of the patient. DESIGN: Prospective, observational, digital, longitudinal real-world study. SETTING: Adult patients with MG from seven countries (USA, Japan, Germany, UK, Italy, Spain and Canada) downloaded a mobile application onto their phones and entered data about themselves and their MG. OUTCOME MEASURES: Data was collected using the following general and disease-specific patient-reported outcome measurements: EuroQol 5 Domains Health-Related Quality of Life Questionnaire (EQ-5D-5L), Myasthenia Gravis Activities of Daily Living (MG-ADL), Myasthenia Gravis Quality of Life 15-item revised scale (MG-QoL-15r), Hospital Anxiety and Depression Scale (HADS) and Health Utilities Index III (HUI3). Patients were categorised by their self-assessed Myasthenia Gravis Foundation of America (MGFA) class (I–V). RESULTS: Baseline results of 841 participants (mean age 47 years, 70% women) are reported. The distribution across the MGFA classes was: 13.9%, 31.0%, 38.1%, 15.5% and 1.6% for classes I–V. The MGFA class was a strong predictor of all aspects of HRQoL, measured with disease-specific and with generic instruments. The domains in which patients with MG most frequently mentioned problems were usual activities, anxiety and depression, tiredness, breathing and vision. The mean total MG-ADL Score was positively associated with increasing MGFA classes: 2.7, 4.4, 6.3 and 8.4 for MGFA classes I–IV. Mean baseline EQ-5D-5L utility was also associated with MGFA classes and was 0.817, 0.766, 0.648 and 0.530 for MGFA class I–IV. CONCLUSIONS: MG has a large impact on key aspects of health and HRQoL. The impact of this disease increases substantially with increasing disease severity. BMJ Publishing Group 2023-01-31 /pmc/articles/PMC9890761/ /pubmed/36720569 http://dx.doi.org/10.1136/bmjopen-2022-066445 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Neurology
Dewilde, Sarah
Philips, Glenn
Paci, Sandra
Beauchamp, Jon
Chiroli, Silvia
Quinn, Casey
Day, Laura
Larkin, Mark
Palace, Jacqueline
Berrih-Aknin, Sonia
Claeys, Kristl G
Muppidi, Srikanth
Mantegazza, Renato
Saccà, Francesco
Meisel, Andreas
Bassez, Guillaume
Murai, Hiroyuki
Janssen, MF
Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG
title Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG
title_full Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG
title_fullStr Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG
title_full_unstemmed Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG
title_short Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG
title_sort patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study myrealworld-mg
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890761/
https://www.ncbi.nlm.nih.gov/pubmed/36720569
http://dx.doi.org/10.1136/bmjopen-2022-066445
work_keys_str_mv AT dewildesarah patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT philipsglenn patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT pacisandra patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT beauchampjon patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT chirolisilvia patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT quinncasey patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT daylaura patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT larkinmark patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT palacejacqueline patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT berrihakninsonia patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT claeyskristlg patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT muppidisrikanth patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT mantegazzarenato patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT saccafrancesco patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT meiselandreas patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT bassezguillaume patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT muraihiroyuki patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg
AT janssenmf patientreportedburdenofmyastheniagravisbaselineresultsoftheinternationalprospectiveobservationallongitudinalrealworlddigitalstudymyrealworldmg